The study, called KOMET and published in The Lancet, has shown that in 1 in every 5 adults with plexiform neurofibromas treated with selumetinib, there was a significant reduction in the tumor.

A rare genetic disorder known as Neurofibromatosis type one, or NF1, affects about one in 2,500 people in the U.S. That's about 120,000 people. Of those, half will develop a subtype--plexiform ...

CHICAGO -- Selumetinib (Koselugo) significantly improved response rates in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas, the phase III KOMET trial ...

The plexiform neurofibroma that was visible on his eyelid also grew back around his eye, squished into his skull, and wrapped around his carotid artery leading to his brain.

Plexiform neurofibroma is a genetic condition that manifests with irregular, thick, ill-defined tumors of the peripheral nerve sheaths. Most are benign, but some can change into cancerous tissue ...

A new, incision-free technique developed at UVA Health to treat debilitating brain lesions called cerebral cavernous malformations, or cavernomas, has shown great promise in early testing, halting ...

Pasithea Therapeutics initiates Phase 1/1b trial of PAS-004 for neurofibromatosis type 1, aiming for patient dosing in Q2 2025.

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business ...

Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business Purchase price of $47 per share in cash represents ...

It is intended for adults with NF1-associated plexiform neurofibromas. Nipoclimab for myasthenia gravis: By the second quarter of 2025, Johnson & Johnson’s IV therapy may be approved for ...

In what ways can NF1-associated plexiform neurofibromas impact QOL, and how do you measure improvements in QOL? One of the obvious ones is cosmesis.

SpringWorks Therapeutics portfolio features Ogsiveo for desmoid tumors and Gomekli for NF1‑plexiform neurofibromas. In fact, Ogsiveo’s revenues alone reached $172 million in 2024, supported by ...